Lentigen has appointed Tim Ravenscroft as its CEO, replacing company founder Boro Dropulic, who continues to serve as president and CSO.
Before joining Lenitgen, Ravenscroft was president of Bristol-Myers Squibb Medical Imaging. He has also held various management positions at Dupont Pharmaceutical and Glaxo Wellcome.
Ravenscroft holds a BS in applied biology from North East London University and an MS in information sciences from City University in the UK, according to Lentigen.
Arrowhead Research, the parent company of RNAi drug developer Calando Pharmaceuticals, has appointed Mauro Ferrari to its newly established board of scientific strategy.
According to the company, the board will provide scientific direction for the company and also make specific recommendations.
Ferrari has held a number of academic positions at institutions including the Brown Foundation Institute of Molecular Medicine and the University of Texas MD Anderson Cancer Center. He holds a PhD in mechanical engineering from the University of California, Berkeley.
Opko Health recently announced that it has appointed Thomas Beier and Richard Pfenniger to its board of directors.
The company also announced the resignation of board member David Eichler. In a filing with the US Securities and Exchange Commission, Opko noted that Eichler’s resignation was not the result of a disagreement with the company.
Pfenniger currently serves as chairman, CEO, and president of Continucare, a provider of physician and practice management services. He will act as chairman of Opko’s audit committee.
Beier is currently director of Ideation Acquisition, a special purpose acquisition company. He will serve on Opko’s audit and compensation committees.